Zestra - first clinically proven arousal solution for women addresses decreased sexual sensation.

(From Chemical Business NewsBase - Press Release)

A new study published in the American Journal of Obstetrics & Gynecology by researchers at Yale School of Medicine and the Albert Einstein College of Medicine reports, "female sexual dysfunction (FSD) affects 48.2% of women and that these women had decreased sensation in the clitoris, which increases the risk of sexual dysfunction." This finding is a landmark development in female sexual function research and provides the underlying reason why major drug companies have been unsuccessful in developing an effective prescription drug treatment for FSD. In 1996, pharmaceutical researcher Martin Crosby recognized that the …